Literature DB >> 23650207

Principal components methods for narrow-sense heritability in the analysis of multidimensional longitudinal cognitive phenotypes.

Wai Lun Alan Fung1, Melissa G Naylor, David A Bennett, Christoph Lange, Deborah Blacker.   

Abstract

BACKGROUND: Genetic association studies of longitudinal cognitive phenotypes are an alternate approach to discovering genetic risk factors for Alzheimer's disease (AD). However, the standard linear mixed model approach is limited in the face of multidimensional longitudinal data and multiple genotypes. In this setting, the principal components of heritability (PCH) approach may increase efficiency by deriving a linear combination of phenotypes to maximize the heritability attributable to a particular genetic locus. The current study investigated the performance of two PCH methods, the Principal Components of Heritability Association Test (PCHAT) and C2BAT, in detecting association of the known AD susceptibility allele APOE-ϵ4 with cognitive function at baseline and decline in cognition over time.
METHODS: PCHAT, C2BAT, and standard linear mixed models were used to test for association between APOE-ϵ4 allele and performance on 19 neuropsychological tests using subjects without dementia at baseline from the Religious Orders Study (ROS) (n = 693) and Memory and Aging Project (MAP) (n = 778). Analyses were conducted across the three methods for three nested phenotype definitions (all 19 measures, executive function and episodic memory measures, and episodic memory only), and for baseline data only versus longitudinal change.
RESULTS: In all cases, APOE-ϵ4 was significantly associated with baseline level of and change over time in cognitive function, and PCHAT and C2BAT yielded evidence of association comparable to or stronger than conventional methods.
CONCLUSION: PCHAT, C2BAT, and other PCH methods may have utility for genetic association studies of multidimensional cognitive and other phenotypes by maximizing genetic information while limiting multiple comparisons.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  cognitive decline; multidimensional longitudinal data; neuropsychological tests; principal components of heritability

Mesh:

Substances:

Year:  2013        PMID: 23650207      PMCID: PMC3758806          DOI: 10.1002/ajmg.b.32151

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  41 in total

1.  Cognitive function and apolipoprotein E in very old adults: findings from the Nun Study.

Authors:  K P Riley; D A Snowdon; A M Saunders; A D Roses; J A Mortimer; N Nanayakkara
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2000-03       Impact factor: 4.077

2.  A random change point model for cognitive decline in Alzheimer's disease and mild cognitive impairment.

Authors:  Lei Yu; Patricia Boyle; Robert S Wilson; Eisuke Segawa; Sue Leurgans; Philip L De Jager; David A Bennett
Journal:  Neuroepidemiology       Date:  2012-07-17       Impact factor: 3.282

3.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

4.  The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons.

Authors:  M N Haan; L Shemanski; W J Jagust; T A Manolio; L Kuller
Journal:  JAMA       Date:  1999-07-07       Impact factor: 56.272

Review 5.  Alzheimer's disease genetics: current knowledge and future challenges.

Authors:  Paul Hollingworth; Denise Harold; Lesley Jones; Michael J Owen; Julie Williams
Journal:  Int J Geriatr Psychiatry       Date:  2010-10-19       Impact factor: 3.485

6.  Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles.

Authors:  David A Bennett; Philip L De Jager; Sue E Leurgans; Julie A Schneider
Journal:  Neurology       Date:  2009-04-28       Impact factor: 9.910

7.  The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period.

Authors:  Robert S Wilson; Julie A Schneider; Lisa L Barnes; Laurel A Beckett; Neelum T Aggarwal; Elizabeth J Cochran; Elizabeth Berry-Kravis; Julie Bach; Jacob H Fox; Denis A Evans; David A Bennett
Journal:  Arch Neurol       Date:  2002-07

8.  Prodromal Alzheimer's disease: successive emergence of the clinical symptoms.

Authors:  Hélène Amieva; Mélanie Le Goff; Xavier Millet; Jean Marc Orgogozo; Karine Pérès; Pascale Barberger-Gateau; Hélène Jacqmin-Gadda; Jean François Dartigues
Journal:  Ann Neurol       Date:  2008-11       Impact factor: 10.422

9.  Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts.

Authors:  Bruce M Psaty; Christopher J O'Donnell; Vilmundur Gudnason; Kathryn L Lunetta; Aaron R Folsom; Jerome I Rotter; André G Uitterlinden; Tamara B Harris; Jacqueline C M Witteman; Eric Boerwinkle
Journal:  Circ Cardiovasc Genet       Date:  2009-02

10.  Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.

Authors:  Adam C Naj; Gyungah Jun; Gary W Beecham; Li-San Wang; Badri Narayan Vardarajan; Jacqueline Buros; Paul J Gallins; Joseph D Buxbaum; Gail P Jarvik; Paul K Crane; Eric B Larson; Thomas D Bird; Bradley F Boeve; Neill R Graff-Radford; Philip L De Jager; Denis Evans; Julie A Schneider; Minerva M Carrasquillo; Nilufer Ertekin-Taner; Steven G Younkin; Carlos Cruchaga; John S K Kauwe; Petra Nowotny; Patricia Kramer; John Hardy; Matthew J Huentelman; Amanda J Myers; Michael M Barmada; F Yesim Demirci; Clinton T Baldwin; Robert C Green; Ekaterina Rogaeva; Peter St George-Hyslop; Steven E Arnold; Robert Barber; Thomas Beach; Eileen H Bigio; James D Bowen; Adam Boxer; James R Burke; Nigel J Cairns; Chris S Carlson; Regina M Carney; Steven L Carroll; Helena C Chui; David G Clark; Jason Corneveaux; Carl W Cotman; Jeffrey L Cummings; Charles DeCarli; Steven T DeKosky; Ramon Diaz-Arrastia; Malcolm Dick; Dennis W Dickson; William G Ellis; Kelley M Faber; Kenneth B Fallon; Martin R Farlow; Steven Ferris; Matthew P Frosch; Douglas R Galasko; Mary Ganguli; Marla Gearing; Daniel H Geschwind; Bernardino Ghetti; John R Gilbert; Sid Gilman; Bruno Giordani; Jonathan D Glass; John H Growdon; Ronald L Hamilton; Lindy E Harrell; Elizabeth Head; Lawrence S Honig; Christine M Hulette; Bradley T Hyman; Gregory A Jicha; Lee-Way Jin; Nancy Johnson; Jason Karlawish; Anna Karydas; Jeffrey A Kaye; Ronald Kim; Edward H Koo; Neil W Kowall; James J Lah; Allan I Levey; Andrew P Lieberman; Oscar L Lopez; Wendy J Mack; Daniel C Marson; Frank Martiniuk; Deborah C Mash; Eliezer Masliah; Wayne C McCormick; Susan M McCurry; Andrew N McDavid; Ann C McKee; Marsel Mesulam; Bruce L Miller; Carol A Miller; Joshua W Miller; Joseph E Parisi; Daniel P Perl; Elaine Peskind; Ronald C Petersen; Wayne W Poon; Joseph F Quinn; Ruchita A Rajbhandary; Murray Raskind; Barry Reisberg; John M Ringman; Erik D Roberson; Roger N Rosenberg; Mary Sano; Lon S Schneider; William Seeley; Michael L Shelanski; Michael A Slifer; Charles D Smith; Joshua A Sonnen; Salvatore Spina; Robert A Stern; Rudolph E Tanzi; John Q Trojanowski; Juan C Troncoso; Vivianna M Van Deerlin; Harry V Vinters; Jean Paul Vonsattel; Sandra Weintraub; Kathleen A Welsh-Bohmer; Jennifer Williamson; Randall L Woltjer; Laura B Cantwell; Beth A Dombroski; Duane Beekly; Kathryn L Lunetta; Eden R Martin; M Ilyas Kamboh; Andrew J Saykin; Eric M Reiman; David A Bennett; John C Morris; Thomas J Montine; Alison M Goate; Deborah Blacker; Debby W Tsuang; Hakon Hakonarson; Walter A Kukull; Tatiana M Foroud; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Gerard D Schellenberg
Journal:  Nat Genet       Date:  2011-04-03       Impact factor: 38.330

View more
  1 in total

Review 1.  Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.

Authors:  David A Bennett; Lei Yu; Philip L De Jager
Journal:  Biochem Pharmacol       Date:  2014-02-06       Impact factor: 5.858

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.